|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.00 HKD | +4.71% |
|
+5.82% | -39.02% |
Company Valuation: VISEN Pharmaceuticals
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Market Cap 1 | 3,095 | 1,798 | - | - |
| Change | - | -41.91% | - | - |
| Enterprise Value (EV) 1 | 2,640 | 1,536 | 1,799 | 1,938 |
| Change | - | -41.82% | 17.11% | 7.77% |
| P/E | -12.1x | -17.5x | -29.4x | - |
| PBR | 4.22x | 3.61x | 4.43x | 16.8x |
| PEG | -0.5x | 0.3x | 0.7x | - |
| Capitalization / Revenue | 18,761x | 26.5x | 4.02x | 2.09x |
| EV / Revenue | 15,999x | 22.7x | 4.02x | 2.25x |
| EV / EBITDA | -12.1x | -6.36x | -10.7x | -11.8x |
| EV / EBIT | -12.7x | -6.25x | -10.5x | -30.5x |
| EV / FCF | - | -11.1x | -13.6x | -31.1x |
| FCF Yield | - | -9.02% | -7.34% | -3.22% |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -2.44 | -0.94 | -0.56 | - |
| Distribution rate | - | - | - | - |
| Net sales 1 | 0.165 | 67.73 | 447.4 | 860.8 |
| EBITDA 1 | -218 | -241.4 | -168.2 | -164.1 |
| EBIT 1 | -208.6 | -245.7 | -170.5 | -63.6 |
| Net income 1 | -253.4 | -99 | -58 | - |
| Net Debt 1 | -455.7 | -262.3 | 0.4861 | 140.2 |
| Reference price 2 | 29.47 | 16.49 | 16.49 | 16.49 |
| Nbr of stocks (in thousands) | 105,021 | 109,035 | - | - |
| Announcement Date | 3/12/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -17.54x | 22.67x | -6.36x | -.--% | 266M | ||
| 32.25x | 5.76x | 17.3x | 1.02% | 46.86B | ||
| -23.62x | 354.58x | -21.66x | -.--% | 40.23B | ||
| 48.91x | 4.94x | 31.87x | -.--% | 36.23B | ||
| 25.32x | 2.8x | 12.1x | -.--% | 34.72B | ||
| 27.42x | 8.04x | 20.17x | 0.41% | 27.89B | ||
| 34.31x | 5.61x | 25.58x | -.--% | 16.79B | ||
| 22.12x | 1.95x | 8.48x | 1.19% | 13.12B | ||
| 23.43x | 1.87x | 11.34x | -.--% | 12.7B | ||
| Average | 19.18x | 45.36x | 10.98x | 0.29% | 25.42B | |
| Weighted average by Cap. | 22.45x | 66.36x | 12.06x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 2561 Stock
- Valuation VISEN Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
















